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Abstract
Background Both long-term proton pump inhibitor (PPI)
use and surgical fundoplication have potential drawbacks
as treatments for chronic gastroesophageal reflux disease
(GERD). This multi-center, prospective study evaluated
the clinical experiences of 69 patients who received an
alternative treatment: endoscopic anterior fundoplication
with a video- and ultrasound-guided transoral surgical
stapler.
Methods Patients with well-categorized GERD were
enrolled at six international sites. Efficacy data was com-
pared at baseline and at 6 months post-procedure. The
primary endpoint was a C50 % improvement in GERD
health-related quality of life (HRQL) score. Secondary
endpoints were elimination or C50 % reduction in dose of
PPI medication and reduction of total acid exposure on
esophageal pH probe monitoring. A safety evaluation was
performed at time 0 and weeks 1, 4, 12, and 6 months.
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and Other Interventional Techniques 
Results 66 patients completed follow-up. Six months
after the procedure, the GERD-HRQL score improved by
[50 % off PPI in 73 % (48/66) of patients (95 % CI
60–83 %). Forty-two patients (64.6 %) were no longer
using daily PPI medication. Of the 23 patients who con-
tinued to take PPI following the procedure, 13 (56.5 %)
reported a C50 % reduction in dose. The mean percent of
total time with esophageal pH \4.0 decreased from base-
line to 6 months (P \ 0.001). Common adverse events
were peri-operative chest discomfort and sore throat. Two
severe adverse events requiring intervention occurred in
the first 24 subjects, no further esophageal injury or leaks
were reported in the remaining 48 enrolled subjects.
Conclusions The initial 6-month data reported in this
study demonstrate safety and efficacy of this endoscopic
plication device. Early experience with the device neces-
sitated procedure and device changes to improve safety,
with improved results in the later portion of the study.
Continued assessment of durability and safety are ongoing
in a three-year follow-up study of this patient group.
Keywords Gastroesophageal reflux disease  Anterior
fundoplication  Proton pump inhibitors  Nissen
fundoplication
Gastroesophageal reflux disease (GERD) is typically the
result of lower esophageal sphincter (LES) dysfunction
caused by inappropriate transient LES relaxation or dimi-
nution of resting basal pressure [1]. GERD is a chronic,
relapsing disease with often under-appreciated adverse
impacts on daily living, work productivity and health-
related quality of life [2]. Consequently, a long-term
management plan is necessary for most patients.
The daily use of proton pump inhibitors (PPI) is generally
effective, although 20–30 % of PPI users are not entirely
satisfied with this treatment [3, 4] and up to 40 % of patients
do not respond or have an incomplete response to PPI therapy
[5–8]. While PPI therapy can heal esophagitis and manage
acid-related heartburn symptoms, it is less effective for ex-
traesophageal symptoms of GERD and in patients with
symptomatic regurgitation [9–13]. Patients may require
increased PPI dosage and other ancillary medications to
control their symptoms [8, 11]. Concerns about the potential
side effects of chronic PPI therapy include increased risk of
bone fracture, infectious complications and interference with
anti-platelet medications, and the absorption of vitamins and
minerals (e.g., B12, calcium, magnesium, iron) [14–16].
The primary alternative to chronic PPI use is surgical
fundoplication and most commonly laparoscopic Nissen
fundoplication (LNF). When performed by experienced
surgeons, long-term results are excellent [17]. Not infre-
quently, however, LNF patients experience problematic
side effects of gaseous bloating, flatulence, diarrhea, dys-
phagia, and the inability to belch or vomit [18, 19]. Inci-
sional hernias have been reported in up to 3 % of
procedures performed at centers of excellence [20]. There
is a broad desire to develop less invasive techniques that
address the GERD symptoms, but reduce the likelihood of
dysphagia and bloating symptoms and do not require
abdominal incision.
Endoscopic anterior fundoplication using a novel
transoral endoscopic device (MUSETM, formerly called
SRS, Medigus, Omer, Israel) has been evaluated as an
alternative GERD therapy. Shown to be safe and techni-
cally facile in animal studies [21], the fundoplication is
created transorally using a video- and ultrasound-guided
surgical stapler. This report describes a multicenter, pro-
spective clinical study to assess the 6-month safety and
efficacy of this procedure which was used to treat 69
patients with GERD.
Materials and methods
Patients
The research protocol and endpoints were designed in close
cooperation with US Food and Drug Administration (FDA)
as an Investigational Device Exemption (IDE) study,
approved by the institutional review board at each study
center and registered at ClinicalTrials.gov (Identifier:
NCT00734747). An independent Data Safety Monitoring
Board (DSMB) advised the sponsor regarding safety of
trial patients as well as the continuing validity and scien-
tific merit of the trial. Training for each investigator con-
sisted of bench top and live porcine procedures, and all
procedures were attended by sponsor medical and engi-
neering personnel. There were no additional training pro-
cedures prior to study enrollment at any site. Six
international centers (3 in Europe, 1 in India, and 2 in the
US) participated. Written informed consent was obtained
from all participants. Patients were recruited directly from
the investigator’s practice or in some cases approved
advertisements. The study included patients aged
18–70 years with C2 years of documented GERD symp-
toms and C6 months of continuous PPI therapy. All sub-
jects were candidates for LNF, according to guidelines of
the Society of American Gastrointestinal and Endoscopic
Surgeons (www.sages.org). Pathologic reflux (off PPI
therapy) was confirmed by ambulatory esophageal pH
monitoring during baseline evaluation. Patients must
demonstrate significant GERD and PPI response by means
of an abnormal GERD- health-related quality of life
(HRQL) questionnaire score of C20 while off PPIs, and
GERD-HRQL score improvement of at least 6 points while
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on PPIs. Patients were excluded if they had a body mass
index [35, or substantial co-morbidities (e.g., heart dis-
ease, diabetes, cancer, previous gastric surgery). Endo-
scopic exclusion criteria included findings of hiatal hernia
C3 cm, Barrett’s esophagus, Los Angeles grade IV
esophagitis or esophageal luminal narrowing including
stricture, ring, or web.
Each patient’s pre-procedure baseline data were com-
pared to data collected 6 months post-procedure to evalu-
ate procedure efficacy, defined as its effect on GERD-
HRQL [22], intra-esophageal acid exposure, PPI use and
anatomical change. Procedure safety was determined by
evaluation of all treatment-related adverse events.
Device and procedure
The device consists of a light source, control unit, and
flexible surgical endostapler which resembles an endo-
scope. The endostapler, designed to be operated by a single
user, includes a handle with controls, a long (80 cm)
flexible shaft, a short (5 cm) rigid section holding a car-
tridge with 5 standard 4.8 mm titanium surgical staples, a
ratchet controlled one-way articulating section, and a distal
tip (Fig. 1A). The distal tip (Fig. 1B) houses an anvil for
bending the staples into a B shape, an ultrasonic transducer,
a miniature video camera, a light source, and two fine
(*21 gage) screws. The screws, secured by two nuts in the
cartridge, provide a means for compressing tissue and a
counterforce for bending the staples. The tip also contains
suction/air insufflation and irrigation channels. The control
unit interprets signals from the device and displays the
resulting data on a video monitor, including the bending
angle and force, ultrasound signal level, screw position,
and the gap between the distal tip and the cartridge.
The procedures were performed under general anesthe-
sia with endotracheal intubation in an operating room or a
therapeutic endoscopy suite. Briefly, the transoral stapler
was advanced into the stomach through an overtube
(17 mm ID/19.5 mm OD) and retroflexed under direct
video guidance. After identifying a stapling location, the
stapler was gently pulled back to place the staple cartridge
in the esophagus approximately 3 cm proximal to the
gastroesophageal junction (Fig. 1C). The operator then
used the articulation knob to bend the device tip to press
the fundus against the esophagus. Next, the screws were
deployed. As the tissues were compressed, and direct
visualization was no longer possible, the ultrasonic range
finder automatically engaged to display the tissue thick-
ness. When the tissue thickness was 1.4–1.6 mm, the
operator fired the stapler. Each firing delivers a quintuplet
pattern of five standard 4.8 mm surgical staples simulta-
neously. The screws were retracted back into the tip of the
device, and the stapler removed for reloading. The proce-
dure was repeated to add additional quintuplets of staples,
as allowed by the protocol. The goal was to mimic a partial
anterior fundoplication, determined by a Hill Grade I valve
[23] so that no esophageal mucosa is visible around the
device in retrograde view (Fig. 2).
Fig. 1 A–C Medigus transoral
surgical stapler: A Full flexible
endostapler, OD 15.5 mm B
Distal tip C positioning of
cartridge 3 cm proximal to
gastroesophageal junction for
stapling
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If a sliding hiatal hernia (SHH) was identified, ventila-
tion with positive end expiratory pressure (PEEP) of
5 mmHg (6.8 cm H20) was applied, and gradually
increased to 10 mmHg (13.6 cm H20) to reduce the
stomach into the abdominal cavity. After the first 24 cases,
the protocol was amended to reduce the pressure gradient
between the abdominal and the thoracic cavity in order to
prevent air leaks around the screws. Subsequently, all
subjects were ventilated with a PEEP setting of 5 mmHg,
after the orotracheal intubation. If SHH was still evident,
PEEP was gradually increased to 10 mmHg until the hernia
was reduced.
Assessment of efficacy and safety
Each patient’s baseline data served as the comparison for
post-procedure evaluation. A GERD-HRQL questionnaire
was administered while patients were off PPI therapy for a
minimum of 7 days. This validated instrument includes six
heartburn-related items and questions relating to other
GERD symptoms, medication use and satisfaction with
present condition. The total GERD-HRQL score ranges
from 0 to 50, with a higher score indicating more severe
symptoms.
Secondary endpoints were elimination or C50 %
reduction in dose of PPI medication, standardized to
40 mg/day of Omeprazole, reduction of total acid exposure
on esophageal pH probe monitoring, and anatomical
changes to the GEFV. Both PPI dose and frequency of PPI
use were recorded at each study visit. At month 6, patients
completed the GERD-HRQL questionnaire and underwent
repeat esophageal pH measurement 5 cm above the man-
ometric border of the LES, esophageal manometry and
standard upper gastrointestinal endoscopy, after the
patients were off PPI therapy for a minimum of 7 days.
Esophageal pH measurements included total percent of
Fig. 2 Step by step endoscopic images of a procedure involving the placement of three quintuplets of staples (15 staples total) to create an
effective gastroesophageal flap valve
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time with pH \4, supine percent of time with pH \ 4,
number of episodes longer than 5 min, and the longest
episode. Esophageal pH was considered normalized if the
total time pH\4 was B4.2 % of time post-procedure [24].
LES pressure and length were recorded, as was peristaltic
amplitude and residual LES pressure during relaxation. An
evaluation of the Hill grade of the gastroesophageal flap
valve (GEFV) as compared with baseline was performed.
Satisfactory flap valve was defined as a grade I or II valve
by the Hill classification.
Adverse events were evaluated at each visit at time 0,
weeks 1, 4, 12, and month 6, as well as at any unscheduled
visits. Serious adverse events were those that resulted in
death, were life-threatening, or required prolongation of a
current hospitalization. Per protocol, hospitalization was
allowed for up to 72 h following the procedure. Hospital-
ization days beyond this period were recorded as a serious
adverse event.
Statistical analysis
The primary endpoint was a C50 % improvement in
GERD-HRQL score in at least 53 % of subjects (lower
bound of confidence interval). This success proportion
was chosen to demonstrate a level of efficacy greater than
that described by Cadiere et al. [25]. For proportions,
exact binomial 95 % confidence intervals were con-
structed. Due to the nonparametric distribution of most of
the continuous data, comparisons between baseline and
post-procedure results were accomplished using Wilcoxon
signed-rank test. The one exception was the evaluation of
PPI dosage which was compared post-procedure to
baseline using a paired t test. Differences in all tests were
considered significant at the P \ 0.05 level. The planned
sample’s size was selected to provide an 80 % chance of
a 95 % one-sided confidence interval excluding a success
proportion of 0.53 if the actual proportion of success was
equal to 0.68. This led to a minimum sample size of 63
patients; however, 72 were enrolled to allow for loss of
follow-up or drop out.
Results
Baseline and procedural results
Seventy-two patients were consented and enrolled across 6
sites and served as the intent-to-treat (ITT) population for
safety analyses (Table 1). A total of 8 patients were
excluded from the 6-month efficacy analysis. Three
patients were excluded upon esophageal screening and did
not receive staple placement. Sixty-nine patients underwent
the full procedure between May 2008 and November 2010.
Three patients were treated, but upon review did not fulfill
the inclusion/exclusion criteria related to initial GERD
severity or improvement in score with PPI. Thus a total of
66 patients were included in the primary efficacy analysis.
Two patients did not complete 6-month follow-up pH and
manometry exams. Therefore, 64 subjects were included in
the secondary efficacy analysis for those parameters
(Table 2). The mean procedural time was 58 ± 38.6 min
in the endoscopy units and 77.7 ± 42.4 min in the oper-
ating rooms. 36 procedures were performed by gast-
roenterologists and 33 by surgeons with established
experience in advanced endoscopic procedures.
Table 1 Demographics and baseline characteristics of enrolled
patients (n = 72)
Female Male
No. of patients 30 42
Age (year); median (range) 56.4 (27–71) 42.2 (24–74)
BMI (kg/m2); mean (range) 26.8 (18.9–35.6) 26.9 (19.3–34 2)
Table 2 Patient enrollment and disposition
No.
Enrolled (ITT population for safety analysis) 72
Enrolled and did not complete procedure (no staples placed) 3
Excluded from primary efficacy analysis (did not meet
inclusion criteria)
3
Total with baseline measures (per protocol and GERD-HRQI at
6 months)
66
Enrolled and refused ‘off-PPI’ testing at the 6-month follow-up
visit
2
Total included in secondary efficacy analysis at 6 months 64
Table 3 Gastroesophageal disease health-related quality of life
(GERD-HRQL) score and sub score analyses at baseline and
6 months post-procedure
GERD-HRQL
Baseline
(On PPi)
Baseline
(Off PPI)
6 months
(Off PPi)
N 66 66 64
Total score, mean (SD) 14.9 (7.5) 29.7 (6.2) 9.0 (9.1)
Total score, median 15 29* 6
Heartburn sub score
(Q1–6) mean (SD)
11.0 (5.8) 21.9 (3.6) 7.2 (7.3)
Heartburn sub score median 11 22* 5
* Wilcoxon Signed-Rank test versus on PP1 baseline value,
P \ 0.001
 Wilcoxon Signed-Rank test versus off PP1 baseline value,
P \ 0.001
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Efficacy analysis
At 6 months, at least 50 % reduction in GERD-HRQL score
(off PPI) from pre-procedure values was achieved in 48 of
66 patients (73, 95 % CI 60–83 %), thus the primary effi-
cacy endpoint was met. Following the procedure, the median
HRQL score (sum of questions 1–10) was significantly
improved relative to the median baseline scores measured
both on and off PPI medication (P \ 0.001) (Table 3).
At baseline, nearly all (65/66) of procedure-treated
patients were taking one or more PPI medications daily
(one patient switched to high dose H2RA after screening).
The average daily dose at baseline per patient was
58.5 ± 33.02 mg/day (standardized to 40 mg Omeprez-
ole). At the 6-month follow-up, forty-two patients (64.6 %)
were no longer using any daily PPI or other acid reducing
medications. For the 23 patients, who continued to use PPI
post-procedure and had 6-month follow-up values, a paired
t test indicated a significant decrease in PPI usage of
31.3 mg/day (t = -3.88, df = 22, P = 0.001) (Table 4).
Eighty-five percent (55/65) of the patients with daily PPI
use at baseline reported a reduction in dose or frequency of
at least 50 % post-procedure (Table 5). Use of occasional
H2RA decreased in dose and frequency from 13 patients to
4 patients post-procedure.
Of the 23 patients, who continued to take PPI medica-
tion following the procedure, 13 (56.5 %) reported at least
a 50 % reduction in dose; seven patients did not change
their PPI usage, two were taking higher doses after than
before the procedure, and one reported PPI usage, but not
the specific dosage.
Additional analysis
GERD-HRQL sub score
Exploratory analysis was performed on the quality of life
scores in patients reported as the sum of questions specifically
related to heartburn (Table 3). In an analysis of GERD-HQRL
questions specific to heartburn (questions 1–6), median sub
scores following the procedure were significantly improved
when compared with baseline sub scores measured both on
and off PPI medication (P \ 0.001) (Fig. 3).
Esophageal pH, manometry, and changes in GEFV
(Hill Grade)
Esophageal pH (off PPI therapy) was measured in 66
patients pre-procedure and in 64 patients at 6 months post-
procedure. Summary analyses indicated statistically sig-
nificant reductions in the means for percent total time and
upright time pH B4, as well as total number of episodes
(Table 6). Analyses for each manometry endpoint are
provided in Table 7. There were no significant changes in
manometry parameters. In an analysis of GEFV Hill Grade
scores, the proportions of patients with an unacceptable
Hill Grade ([2) before (0.661, 43/65) and after (0.062,
4/65) the procedure were statistically different (P \ 0.0001
per McNemar test) (Table 8).
Fig. 3 Boxplots of GERD-HRQL median scores at baseline
(N = 66) and 6 months post-procedure (N = 64)
Table 4 PPI utilization
Baseline
(N = 66)
6 month
(N = 66)
Patients taking 1 or more PPI 65 23
Dose, mg/day; mean (SD) 58.5 (33.0) 31.3 (11.4)*
Dose, mg/day; mean 40 30
* P = 0.001 versus baseline (paired-1-test) only for the 23 patients
that had baseline and follow-up values
Table 5 No. of patients using proton pump inhibitor (PPI) medica-
tion 6 months post-procedure
N (%) 95 % CIa
PPI eliminated or reduced C50 %
Off all PPIs 42/65 (65 %) (52, 76)
Dose reduced \50 % 55/65 (85 %) (74, 92)
Medication PPI not eliminated\not
reduced C50 %
Dose reduced \50 % 10/65 (15 %) (8, 26)
Dose maintained 7/65 (11 %) (4, 21)
Dose increased 2/65 (3 %) (0, 11)
a Exact binomial 95 % CI
Surg Endosc (2015) 29:220–229 225
123
Safety results and side effects
At 6 months there were no residual serious adverse events
related to the device or the procedure. In the final 48/72
subjects enrolled, there were two SAEs, neither of which
required intervention. One was rated mild in severity
requiring additional inpatient observation for elevated
C-Reactive Protein (CRP). Another was non-procedure
related involving an overnight hospitalization for a psy-
chiatric emergency 35 days post-procedure.
However, there were eight SAEs recorded in the first
24 subjects (Table 9). Four were rated as mild and tran-
sitory. Three of these were kept in hospital for observa-
tion an additional 24 h over the defined limit of 72 h, and
one was readmitted for 1 day. All four had normal en-
doscopies and radiological studies. Two SAEs were rated
as moderate, with findings of pneumomediastinum and/or
pneumoperitoneum. Both patients were asymptomatic and
recovered uneventfully without intervention, but were
hospitalized for observation an additional 4 and 14 days,
respectively. Two SAEs were rated as severe and required
intervention. The first involved a subject who returned to
the hospital 3 days post-procedure with empyema and
pneumothorax, although the immediate post-procedure
chest roentgenogram was normal. A perforation was not
demonstrated on endoscopy or by radiological (contrast
CT and fluoroscopy) studies, but the drained fluid had
high amylase concentration indicative of an esophageal
leak. This patient underwent chest tube and antibiotic
therapy and recovered after a hospitalization of 22 days.
There were no long-term sequelae in follow-up. The
subject had severe retching post-anesthesia, which likely
caused excessive tension on one or both of the stapling
sites. The second severe SAE was an upper gastrointes-
tinal hemorrhage which presented 8 days after the pro-
cedure. The patient was re-hospitalized for 72 h and
received a two-unit transfusion. Endoscopy did not reveal
a source, and recovery was complete.
The interim review of these early SAEs resulted in
protocol and device changes implemented after the first
24 subjects to mitigate risks. It was noted that six of the
SAEs were in subjects that received only two staplings,
therefore an additional stapling was encouraged with the
aim of reducing stress at an individual stapling site. The
protocol was also amended to require prophylactic ther-
apy to prevent immediate post-operative retching which
can also stress stapling sites, and to require a chest X-ray
to confirm no leaks are present prior to discharge. In
addition, device changes were made to prevent air
insufflation during screw insertion in order to prevent the
tendency of air to leak into the peritoneum around the
screws before the staples are formed. Following these
amendments and procedural changes there were no further
cases of leak or pneumomediastinum in the next 48
subjects enrolled.
The most common adverse events reported were chest
pain in 22 % (16/72) and sore throat in 21 % (15/72) of
patients. AE’s occurring in more than 5 % of patients was
atelectasis, pain in the shoulder, and increased belching.
All resolved spontaneously and the majority were reported
in the immediate post-operative period (Table 10). There
were no reports of dysphagia, bloating, or inability to
belch.
Table 6 Summary of esophageal pH measures
Symptom Baseline (off
PPI)
6 months (off
PPI)
P value*
n Mean (SD) n Mean (SD)
pH B 4 (%) total 66 10.9 (10.7) 64 7.3 (5.1) \0.001
pH B 4 (%)
upright
66 12.0 (11.3) 60 8.5 (6.1) 0.013
pH B 41 (%)
supine
66 6.8 (11.0) 59 5.4 (6.9) 0.48
Total episodes 66 170.8
(181.6)
64 100.4
(105.9)
\0.001
Longest episode
(min)
66 23.9 (22.1) 63 21.1 (20.0) 0.28
* P value versus baseline Wilcoxon signed-rank test
Table 7 Summary of esophageal manometry data
Physiologic measurement Baseline Month 6 P value*
LES pressure (mmHg)
N 64 58
Mean (SD) 11.6 (8.6) 12.5 (8.0)
Median 9.85 11.15 0.43
LES length (cm)
N 62 58
Mean (SD) 40.9 (17.7) 36.5 (18.7)
Median 40.0 35.0 0.16
Peristaltic amplitude (mmHg)
N 64 58
Mean (SD) 78.8 (35.8) 80.7 (40.1)
Median 70.0 68.5
* P value versus baseline Wilcoxon signed-rank test
Table 8 Hill grades at baseline: pre- and post-procedure
6-month post-procedure
Grade B2 Grade [2 Total
Baseline (pre-procedure)
Grade B2 21 1 22
Grade [2 40 3 43
Total 61 4 65
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Discussion
PPI therapy and LNF have been the mainstay of GERD
treatment. Their limitations and adverse effects have led to
the development of currently marketed alternative thera-
pies including StrettaTM, EsophyxTM, LinxTM and others
[26–30].
Unlike other procedures, the endostapler closely mimics
surgical anterior fundoplication through transoral stapling.
The device incorporates a video camera for direct visuali-
zation during insertion and staple site selection and ultra-
sound to determine when a proper stapling gap is achieved.
In this report, the majority of patients treated with the en-
dostapler had improved symptom control of GERD and no
longer needed daily PPI therapy at 6 months.
Additional exploratory analysis revealed that the
GERD-HRQL sub score of heartburn-related questions was
also improved for post-procedure patients even as com-
pared with those on PPI pre-procedure. These data further
serves to illustrate that the procedure can relieve heartburn
symptoms and provide an effective alternative to chronic
PPI use.
The procedure may not preclude future surgical fundo-
plication; two subjects elected to have a LNF after con-
clusion of the study and this was accomplished without
difficulty. The current protocol mandated hospitalization
and observation of all subjects; however, the procedure
may eventually be performed in an outpatient setting as
experience increases.
Important limitations in the design of this study include
a short follow-up period and the lack of a sham or control
group. Further study is planned. Three-year follow-up data
is being collected and will be reported. The study excluded
the subset of patients with relatively common GERD
complications such as large hiatal hernia, severe erosive
esophagitis, and symptoms non-responsive to PPI therapy,
Barrett’s esophagus and esophageal motility disorders.
New studies will be necessary to determine the safety and
efficacy of the device in such patients.
There were no post-procedure reports of common
problems seen with LNF such as gas bloating, inability to
belch or vomit, and dysphagia. Most adverse events were
reported in the immediate peri-operative period and were
most commonly chest pain or sore throat.
Table 9 Summary of SAEs SAE Sex Age
(years)
Days after
procedure
Duration
(days)
Rating Life
threatening
SAE description
N = 24 subjects enrolled
1 M 51.1 2 2 Mild No Pain and fever
2 M 55.1 1 4 Mild No Pain and fever
3 M 29.1 1 14 Moderate No pneumomediastinum
4 F 66.9 16 1 Mild No Pain in the thorax
5 F 55.3 1 4 Moderate No Pneumothorax
pneumoperitoneum
6 M 37.2 8 1 Mild No Viral infection
7 M 38.1 3 22 Severe No Pneumothorax
Pleural effusion
Esophageal leak
8 M 32.1 8 3 Severe No Upper GI bleed
Interim safety analysis: implementation of protocol and device changes
N = 48 subjects enrolled
9 M 45.8 35 1 Severe No Suicidal behavior
10 F 61.3 4 1 Mild No Fever, elevated CRP
Table 10 Device- and/or
procedure-related AEs in 5 % or
more of patients
a 1 event occured 19 days
following the procedure
Adverse event Post-procedure
to discharge
1 week (6–10 days
post-procedure)
2 weeks (±4 days) Total Events/subject
(N = 72)
Chest pain 15 1 16 22 %
Sore throat 15 15 21 %
Atelectasis 6 6 8.3 %
Shoulder pain 5 2a 5 6.9 %
Increase belching 4 4 5.5 %
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There were no run-in procedures for this study. As such,
serious adverse events were concentrated in the first 24
subjects. The use of anti-retching prophylaxis, increased
number of staplings, and insufflation control during the
screw deployment resulted in a much improved safety
profile in the remaining 48 subjects enrolled with no
additional cases of leakage or pneumomediastinum repor-
ted. Trials using CO2 insufflation would be of interest. As
with many new procedures, the safety and effectiveness
profile should continue to improve as experience is gained
and a newer generation device is introduced.
In conclusion, this study reports early experience of an
endoscopic stapler for patients with chronic GERD. As a
result of this study, the system was FDA cleared and CE
marked for endoscopic placement of surgical staples in the
soft tissue of the esophagus and stomach in order to create
an anterior partial fundoplication for treatment of symp-
tomatic chronic GERD in patients who require and respond
to pharmacological therapy. The procedure is an option to
offer patients looking for reduction or discontinuance of
GERD medical therapy, and avoidance of problematic side
effects associated with incisional therapies such as LNF.
Longer term follow-up of this patient group is underway.
An improved version of the system has recently been
cleared with an improved user interface. Additional studies
in a larger patient population are needed and will assess
this new system for safety and effectiveness before con-
clusions of the procedure durability can be established.
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